Radar · Immunology in United States
Best Immunology Companies in United States
The 636 best Immunology companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sana Biotechnology.
By Riya SenguptaFinancials
636companies tracked
$33.3Bdisclosed funding
3unicorns
434have raised
Ranking the most-funded Immunology companies across the United States, this directory tracks 636 ventures carrying $33.3B in total disclosed funding, three unicorns among them. The sector's CAGR sits at roughly 7.5%, driven by biotech alliances, accelerating R&D spend, and favorable approval frameworks that keep capital moving. Immunic leads our funding table at $560M, with Mirador close behind at $480M and Evommune at $268M. Backers including RA Capital Management, OrbiMed, and HHS are doing the heaviest lifting.
So what does earned revenue actually look like here? Across seven validated filers, median revenue lands at $18M with 14% YoY growth, and the combined pool reaches $498M. But the distribution is brutal. Apellis Pharmaceuticals pulled $268M, 15x the sector median, while Adma Biologics logged $114M (6x) and Aurinia Pharmaceuticals $78M (4x). I'd note that hot research themes right now, vaccine immunogenicity and immune response measurement among them, are shaping where the next revenue leaders emerge. You're looking at a sector where a handful of filers dwarf the field, and the gap between funded and earning is still very wide.
Ranked: Best Immunology companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant Provider of therapeutics solutions for treating autoimmune diseases 29Funding top 16%News top 45%Moat top 48%Tech bottom 48% All 7 signals ▾Fundingtop 16% Newstop 45% Moattop 48% Techbottom 48% Growthbottom 47% Globalbottom 41% Marketbottom 25% Funding: Raised $685M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) News: 7 BI events in 12 mo (of 46 tracked, 7 types) · -50% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $685M | 17 mo ago | 1 | — | Apple iCloud MailBootstrapAmazon Web Services+20 | 7 signals ▼50% Earnings · Funding · Leadership | — | — |
| 2 | Eikon 🦄 Protein tracking and measuring tool for drug discovery 60Funding top 14%News top 28%Moat top 28%Market top 38% All 10 signals ▾Fundingtop 14% Newstop 28% Moattop 28% Markettop 38% Growthtop 40% Techtop 43% Talenttop 44% Globalbottom 42% Patentsbottom 38% Innovationbottom 36% Funding: Raised $668M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 8 BI events in 12 mo (of 23 tracked, 7 types) · +14% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $668M | 16 mo ago | 331 | Robert Tjian Co-Founder | WordPressApple iCloud MailMicrosoft 365+23 | 8 signals IPO · Leadership · Earnings | 9 patents Automated vehicle intrusion barriers for rapid security deployment | — |
| 3 | Generate Biomedicines 🦄 Developer of a platform for generating novel protein-based therapeutic modalities 78AI top 18%Funding top 23%News top 24%Innovation top 25% All 12 signals ▾AItop 18% Fundingtop 23% Newstop 24% Innovationtop 25% Growthtop 25% Patentstop 25% Moattop 25% Talenttop 28% Markettop 45% Techbottom 43% Globalbottom 42% Fin. healthbottom 39% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $643M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 78/100 | $643M | 17 mo ago | 75 | Gevorg Grigoryan Co-Founder & CTO | Craft CMSApple iCloud MailPHP+17 | 6 signals IPO | 36 patents Patents concentrated in chemistry & materials | — |
| 4 | Immunic Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases 35Funding top 19%Tech top 41%Moat top 48%Growth top 50% All 9 signals ▾Fundingtop 19% Techtop 41% Moattop 48% Growthtop 50% Talentbottom 49% Globalbottom 45% Newsbottom 40% Marketbottom 38% Fin. healthbottom 20% Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud rank vs industry peers · Fliar Intelligence Index 35/100 | $560M | 4 mo ago | 77 77 → 91 (+18%) · sector median +23% | Daniel Vitt Chief Executive Officer | Froala EditorPHPHighcharts+18 | 3 signals ▼77% Funding | — | — |
| 5 | Alumis Developer of therapeutics for the treatment of auto-immune disease | $529M | 23 mo ago | 16 | Martin Babler CEO | DrupalApple iCloud MailMicrosoft 365+21 | 10 signals ▼41% Earnings · IPO · Announcements | 88 patents TYK2 kinase inhibitor compounds and formulations for inflammatory disease treatment. | — |
| 6 | Odyssey Developer of immunotherapeutics for immunological and cancer diseases 74Funding top 12%Growth top 13%Talent top 28%Moat top 31% All 7 signals ▾Fundingtop 12% Growthtop 13% Talenttop 28% Moattop 31% Techbottom 46% Marketbottom 45% Globalbottom 39% Funding: Raised $503M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Growth: Headcount 50 → 108 (+116%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $503M | 12 mo ago | 108 108 → 118 (+9%) · sector median +23% | Paul-Albert König Co-Founder and Sr. Director Biology | WordPressApple iCloud MailMicrosoft 365+22 | — | — | — |
| 7 | Mirador Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases 50Funding top 15%Growth top 35%Moat top 42%Tech top 44% All 9 signals ▾Fundingtop 15% Growthtop 35% Moattop 42% Techtop 44% Producttop 49% Talentbottom 49% Newsbottom 38% Globalbottom 36% Marketbottom 32% Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 50/100 | $480M | 5 mo ago | — | Mark McKenna Founder & CEO | WordPressApple iCloud MailMicrosoft 365+21 | — | — | — |
| 8 | 180 Life Sciences Developer of drugs for treating inflammatory diseases | $440M | 10 mo ago | 7 | — | WordPressMySQLPHP+17 | — | — | — |
| 9 | AvenCell Developer of next-generation switchable CAR T-cell immunotherapies 40Funding top 17%Moat top 42%Talent bottom 49%Market bottom 45% All 6 signals ▾Fundingtop 17% Moattop 42% Talentbottom 49% Marketbottom 45% Globalbottom 45% Techbottom 35% Funding: Raised $362M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 40/100 | $362M | 11 mo ago | 67 | Andrew Schiermeier Chief Executive Officer | WordPressApple iCloud MailMySQL+16 | — | — | — |
| 10 | Orca Bio 🦄 Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders 74Funding top 18%Growth top 26%Moat top 26%Talent top 38% All 8 signals ▾Fundingtop 18% Growthtop 26% Moattop 26% Talenttop 38% Techtop 40% Markettop 42% Globalbottom 37% Newsbottom 18% Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $300M | 5 mo ago | 66 | Jeroen Bekaert Co-Founder & COO | WordPressApple iCloud MailGoogle Workspace+29 | — | — | 1 expansion |
| 11 | Arrowhead Pharmaceuticals Developer of therapeutics to treat multiple diseases | $290M | 12 mo ago | 427 427 → 809 (+89%) · sector median +23% | Christopher Anzalone CEO & President | DrupalApple iCloud MailMicrosoft 365+25 | 20 signals ▲67% Earnings · Funding · Contracts | 1,202 patents RNA interference therapeutics targeting disease genes and targeted delivery systems | — |
| 12 | Avalyn Pharma Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis 57Funding top 14%Growth top 30%News top 30%Moat top 31% All 7 signals ▾Fundingtop 14% Growthtop 30% Newstop 30% Moattop 31% Techtop 40% Globalbottom 39% Marketbottom 36% Funding: Raised $289M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $289M | 10 mo ago | 24 | — | WordPressApple iCloud MailMySQL+25 | 5 signals ▲25% IPO | — | — |
| 13 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | 949 | Henry Ji Co-Founder & CEO | — | — | 1,073 patents Patents concentrated in health & consumer products | — |
| 14 | Evommune Developer of therapeutic options for chronic inflammatory disorders 60Growth top 16%Funding top 18%News top 25%Tech top 47% All 10 signals ▾Growthtop 16% Fundingtop 18% Newstop 25% Techtop 47% Fin. healthtop 47% Moattop 47% Patentsbottom 47% Marketbottom 46% Innovationbottom 42% Globalbottom 39% Growth: Revenue +86% YoY · Fresh capital in last 24 mo Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $268M | 4 mo ago | 33 | — | WordPressMySQLPHP+20 | 15 signals ▲650% IPO · Earnings · M&A | 3 patents Small-molecule PKCθ inhibitors for immune‑modulating therapeutics | 2 launchs · 1 partnership |
| 15 | Umoja Biopharma Developer of cancer therapeutics | $263M | 17 mo ago | 168 | Michael Jensen Co-Founder | WordPressMySQLPHP+18 | — | 132 patents Lentiviral vector production and engineered stem‑cell/immune cell therapies for oncology | — |
| 16 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 16 mo ago | 24 24 → 40 (+67%) · sector median +23% | — | WordPressMySQLPHP+13 | — | 48 patents Therapeutic anti‑KLRG1 antibodies for treating immune‑cell malignancies and autoimmune diseases | — |
| 17 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 3 mo ago | 12 12 → 23 (+92%) · sector median +23% | — | Apple iCloud MailMicrosoft 365Bootstrap+8 | — | 107 patents CCR5-targeted biologics for HIV, cancer, NAFLD/NASH and immune‑modulating therapies | 1 partnership |
| 18 | SetPoint Medical Developer of implantable neuromodulation devices for inflammatory diseases 72Funding top 18%Product top 18%Innovation top 19%Patents top 22% All 10 signals ▾Fundingtop 18% Producttop 18% Innovationtop 19% Patentstop 22% Growthtop 24% Newstop 24% Moattop 26% Techtop 49% Globalbottom 42% Marketbottom 40% Funding: Raised $248M across 11 rounds · 11 rounds over 17 yrs (0.6/yr) Product: 8 distinct product lines · Company stage: Series F rank vs industry peers · Fliar Intelligence Index 72/100 | $248M | 14 mo ago | 46 | — | WordPressApple iCloud MailMicrosoft 365+20 | 8 signals Funding | 157 patents Bioelectronic neuromodulation devices targeting vagus nerve for chronic inflammation control | 1 launch · 1 partnership |
| 19 | Candid Therapeutics Developer of therapeutics for autoimmune diseases 40Funding top 17%Growth top 38%News top 48%Moat top 48% All 8 signals ▾Fundingtop 17% Growthtop 38% Newstop 48% Moattop 48% Talentbottom 49% Techbottom 38% Globalbottom 38% Marketbottom 32% Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $206M | 3 mo ago | — | Ken Song CEO | WordPressMySQLPHP+15 | 4 signals M&A | — | — |
| 20 | Noveome Developer of biologically active molecules for the treatment of Periodontitis and inflammation diseases | $170M | 13 mo ago | 15 15 → 30 (+100%) · sector median +23% | — | WordPressBugHerdMySQL+25 | — | — | — |
| 21 | Shattuck Labs Developer of an immunotherapy platform for oncology and other diseases | $165M | 9 mo ago | 89 89 → 57 (-36%) · sector median +23% | — | WordPress Block EditorWordPressApple iCloud Mail+20 | 3 signals ▼57% Earnings · Funding | 305 patents Bispecific immunomodulatory antibodies and TRIM7‑targeted protein therapeutics, including mRNA formats. | — |
| 22 | Third Arc Bio Developer of therapetics for cancer and immunological diseases 37Funding top 20%Talent top 38%Moat bottom 48%Tech bottom 47% All 7 signals ▾Fundingtop 20% Talenttop 38% Moatbottom 48% Techbottom 47% Globalbottom 36% Marketbottom 32% Newsbottom 18% Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $165M | 4 mo ago | — | Sanjaya Singh Founder & Chief Scientific Officer | GSAPReactGatsby+15 | — | — | — |
| 23 | Bryn Pharma Developer of nasal based epinephrine for anaphylaxis 10Funding top 26%Talent bottom 49%Global bottom 29%News bottom 24% All 6 signals ▾Fundingtop 26% Talentbottom 49% Globalbottom 29% Newsbottom 24% Marketbottom 20% Techbottom 17% Funding: Raised $123M across 6 rounds · 6 rounds over 8 yrs (0.8/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 10/100 | $123M | 14 mo ago | 10 | David Dworaczyk Retired CEO: Corporate Advisor/Consultant to Bryn Pharma | PleskWindows ServerMicrosoft ASP.NET+10 | — | — | — |
| 24 | CREATE Medicines Developer of messenger ribonucleic acid therapies for immune cell programming 50Funding top 20%Patents top 41%Innovation top 47%Talent bottom 49% All 5 signals ▾Fundingtop 20% Patentstop 41% Innovationtop 47% Talentbottom 49% Globalbottom 35% Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $122M | 1 mo ago | — | Daniel Getts Co-Founder & CEO | — | — | 18 patents Therapeutic chimeric fusion proteins and gene/miRNA delivery platforms for drug development | — |
| 25 | RegCell Developer of cell therapies focused on restoring immune tolerance for autoimmune diseases | $117M | 15 mo ago | — | Shimon Sakaguchi Founder | WordPressMySQLPHP+10 | — | — | — |
| 26 | RayThera Developer of small molecule therapies for unmet needs in immunology | $110M | 14 mo ago | — | Gene Hung Co-Founder & CSO | — | — | 12 patents Peptide-based modulators targeting Jak2 V617F, TNF‑α, CCR4, and STAT6 signaling | — |
| 27 | Mediar Therapeutics Developer of antibody-based therapeutics for treating fibrosis 19Funding top 25%Moat top 48%Talent bottom 49%News bottom 42% All 6 signals ▾Fundingtop 25% Moattop 48% Talentbottom 49% Newsbottom 42% Globalbottom 39% Marketbottom 21% Funding: Raised $105M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · 9 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $105M | 6 mo ago | 2 | Rahul Ballal CEO | — | — | — | — |
| 28 | Nocion Therapeutics Developer of therapeutics for the treatment of multiple diseases 42Funding top 23%Talent top 28%Moat top 39%Global bottom 39% All 6 signals ▾Fundingtop 23% Talenttop 28% Moattop 39% Globalbottom 39% Marketbottom 34% Newsbottom 18% Funding: Raised $104M across 4 rounds · 4 rounds over 7 yrs (0.6/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $104M | 6 mo ago | 15 15 → 19 (+27%) · sector median +23% | Clifford Woolf Co-Founder | — | — | — | — |
| 29 | Immunomic Therapeutics Vaccines for allergy, cancer and infectious disease. 57Funding top 24%Growth top 28%Product top 30%Innovation top 34% All 9 signals ▾Fundingtop 24% Growthtop 28% Producttop 30% Innovationtop 34% Moattop 39% Techbottom 44% Marketbottom 37% Globalbottom 37% Newsbottom 21% Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $98M | 12 mo ago | 51 | — | WordPressMySQLPHP+28 | — | — | — |
| 30 | CalciMedica Developer of CRAC channel inhibitor drugs for inflammatory diseases | $87M | 14 mo ago | 11 | — | WordPressMySQLPHP+19 | — | 271 patents CRAC channel inhibitor drugs for inflammatory lung and pancreatic disorders | — |
| 31 | TRexBio Developer of therapeutics for immunology and cancer 45Funding top 20%Moat top 31%News top 46%Talent bottom 49% All 6 signals ▾Fundingtop 20% Moattop 31% Newstop 46% Talentbottom 49% Marketbottom 47% Globalbottom 36% Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $85M | 4 mo ago | 65 | Johnston Erwin CEO | — | — | — | — |
| 32 | Electra Therapeutics Developer of therapies for immunological diseases and cancer | $84M | 8 mo ago | 4 | Adam Rosenthal Co-Founder & CEO | — | — | — | 1 launch |
| 33 | Zag Bio Developer of thymus-targeted medicines for autoimmune disease treatment and prevention | $80M | 7 mo ago | — | Diane Mathis Co-Founder | — | — | — | — |
| 34 | EpiBiologics Developer of antibody-based targeted therapies to treat multiple diseases 45Funding top 21%Talent top 38%Moat top 39%Innovation top 42% All 7 signals ▾Fundingtop 21% Talenttop 38% Moattop 39% Innovationtop 42% Patentstop 42% Globalbottom 37% Marketbottom 34% Funding: Raised $73.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $73M | 5 mo ago | 22 | Josef Gramespacher Co-Founder | — | — | 13 patents Bispecific antibody therapeutics for targeted degradation of EGFR and cMET receptors | 1 job opening |
| 35 | Excellergy Developer of trifunctional effector cell response inhibitors for allergic diseases | $70M | 8 mo ago | — | Theodore Jardetzky Co-Founder | WordPressMySQLPHP+24 | — | 5 patents Therapeutic antibodies and fragments that bind IgE for allergy treatment | — |
| 36 | Therini Bio Limited information available | $62M | 13 mo ago | 13 13 → 15 (+15%) · sector median +23% | Daniel Burgess CEO | — | — | — | — |
| 37 | Sparrow Pharmaceuticals Developer of drugs for the treatment of endocrine disorders | $61M | 11 mo ago | 10 | — | — | — | — | — |
| 38 | Celdara Medical Developer of therapeutics for the treatment of multiple diseases 21Funding top 30%Talent bottom 49%Tech bottom 38%Global bottom 32% All 6 signals ▾Fundingtop 30% Talentbottom 49% Techbottom 38% Globalbottom 32% Marketbottom 28% Newsbottom 22% Funding: Raised $46.5M across 37 rounds · 37 rounds over 17 yrs (2.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 21/100 | $46M | 12 mo ago | 16 16 → 19 (+19%) · sector median +23% | Jake Reder CEO | — | — | — | — |
| 39 | Viridian Therapeutics Developer of medicines for patients with serious and rare diseases | $34M | 1 mo ago | 94 | — | BugHerdApple iCloud MailQ4+19 | 8 signals ▲167% Regulatory · Funding · Earnings | — | — |
| 40 | Rapafusyn Developer of therapeutics for treatment of multiple diseses | $28M | 9 mo ago | 3 | Sean Hu CEO | — | — | — | — |
| 41 | Athos Therapeutics Developer of AI-based therapeutics for treating autoimmune diseases 35AI top 35%Funding top 36%Talent bottom 49%Moat bottom 45% All 6 signals ▾AItop 35% Fundingtop 36% Talentbottom 49% Moatbottom 45% Marketbottom 32% Globalbottom 25% AI: Product described with: ai-based, machine learning Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 2 mo ago | 18 | Dimitrios Iliopoulos Co-founder | — | — | — | — |
| 42 | Cue Biopharma Precision immunotherapies to transform patients' lives by selectively modulating the immune system 67Innovation top 16%Patents top 16%News top 28%Moat top 29% All 11 signals ▾Innovationtop 16% Patentstop 16% Newstop 28% Moattop 29% Growthtop 31% Partnerstop 32% Fundingtop 36% Fin. healthtop 37% Marketbottom 49% Globalbottom 35% Techbottom 32% Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21 Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $26M | 1 mo ago | 51 51 → 39 (-24%) · sector median +23% | — | WordPress Block EditorWordPressMySQL+15 | 16 signals ▲45% Board · Leadership · Earnings | 491 patents T-cell engaging biologics for immune modulation and B-cell depletion therapies | — |
| 43 | Kiora Pharmaceuticals Developer of therapies for the treatment of different types of eye diseases | $20M | 2 mo ago | 12 12 → 17 (+42%) · sector median +23% | Brian Strem CEO | WebflowWordPressMySQL+23 | — | — | 1 launch |
| 44 | GEn1E Developer of therapeutics for the treatment of inflammatory and rare diseases | $17M | 7 mo ago | 19 | Ritu Lal Co-Founder & CEO | — | — | — | — |
| 45 | Iolyx Therapeutics Developer of therapeutics for autoimmunity and ophthalmological conditions | $15M | 6 mo ago | — | Elizabeth Jeffords CEO & President | — | — | — | — |
| 46 | ParcelBio Developer of programmable technology to deliver mRNA to diverse cell types in the body | $13M | 4 mo ago | — | Christopher Carlson Co-Founder | — | — | — | — |
| 47 | TippingPoint Biosciences Developer of therapeutics for treating diseases caused by dysfunctional genome chromatin packaging | $7M | 2 mo ago | — | Geeta Narlikar Co-Founder | WebflowGoogle Mapslit-html+13 | — | — | 1 partnership |
| 48 | Remedium Bio Developer of gene therapies for a broad range of diseases 7Funding top 37%Moat top 48%Global bottom 36%Tech bottom 22% All 5 signals ▾Fundingtop 37% Moattop 48% Globalbottom 36% Techbottom 22% Marketbottom 20% Funding: Raised $5.6M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 7/100 | $6M | 1 mo ago | 5 | — | Google MapsBootstrapNginx+6 | — | — | 1 job opening |
| 49 | Praeventix Developer of novel serotonergic therapeutics for multiple diseases | $4M | 4 mo ago | — | Douglas Pippin Founder & CEO | — | — | 68 patents Novel lactam-based compounds targeting the 5‑HT7 serotonin receptor for therapeutic use | — |
| 50 | Ancilia Developer of microbiome therapies for immunology and oncology indications 19Funding top 37%Patents top 41%Innovation bottom 49%Moat bottom 49% All 7 signals ▾Fundingtop 37% Patentstop 41% Innovationbottom 49% Moatbottom 49% Globalbottom 43% Marketbottom 20% Newsbottom 18% Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $4M | 4 mo ago | 5 | — | — | — | 11 patents Blockchain security analytics and microbiome modulation therapeutics | — |
Top 12 Immunology companies in United States
#1
Public · New York City, New York · founded 2003 · 77 employees$559.7Mraised▾
Public · New York City, New York · founded 2003 · 77 employees
Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. The product pipeline of the company includes vidofludimus calcium (IMU-838), a selective immune modulator for multiple sclerosis, IMU-935, a selective inverse agonist targeted for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome and IMU-856, for bowel barrier dysfunction.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 19%Tech
top 41%Moat
top 48%Growth
top 50%Talent
bottom 49%Global
bottom 45%Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Post IPO (Feb 2026)
Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud · Security: Cloudflare Bot Management, Hsts
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 12k LinkedIn followers — 2.7% of this cohort's audience
Funding rounds
- Feb 2026Post IPO$400M
- Jan 2024Post IPO$80M
- Oct 2022Post IPO$60M
- Sep 2016Post IPO$19.7M
Founders & team
Investors
BVF Partners, Janus Henderson Investors, Soleus Capital, RTW Investments, Adage Capital Management, Avidity Partners
Tech stack
Apache Http ServerBricksCloudflareCloudflare Bot ManagementCookiebotCore-Js
#2
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Public · Vancouver, Washington · founded 2002 · 12 employees
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 17%Growth
top 35%Patents
top 36%Innovation
top 44%Moat
bottom 49%Global
bottom 36%Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) · Last round Post IPO (Mar 2026)
Growth: Fresh capital in last 24 mo
Patents: 107 patents matched (strict assignee match) · 25 filings since 2022 vs 49 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Natera) announced in 12 mo
Funding rounds
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
Investors
Cool Blue Capital, Centrecourt Asset Management, 4-Good Ventures
Tech stack
Amazon Web ServicesApache Http ServerApple Icloud MailBootstrapFancyboxGoogle Analytics
#3
Public · Sacramento, California · founded 2020 · 33 employees$268Mraised▾
Public · Sacramento, California · founded 2020 · 33 employees
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Growth
top 16%Funding
top 18%News
top 25%Tech
top 47%Fin. health
top 47%Moat
top 47%Growth: Revenue +86% YoY · Fresh capital in last 24 mo
Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Post IPO (Feb 2026)
News: 15 BI events in 12 mo (of 26 tracked, 6 types) · +650% YoY · 14 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 2 product launches · 1 partnerships (incl. Maruho Co Ltd.) announced in 12 mo
Funding rounds
- Feb 2026Post IPO$125M
- Oct 2024Series C$115M
- Jun 2023Series B$7.5M
- Mar 2023Series B$57.5M
Investors
Andera Partners, Life Sciences Partners, Pivotal bioVenture Partners, RA Capital Management, Sectoral, RTW Investments
Tech stack
Amazon Web ServicesAosApache Http ServerBootstrapCloudflareCloudflare Bot Management
#4
Series B · San Diego, California · founded 2023$480Mraised▾
Series B · San Diego, California · founded 2023
Developer of therapeutics for immune-mediated inflammatory and fibrotic diseases. The company’s Mirador360 precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 15%Growth
top 35%Moat
top 42%Tech
top 44%Product
top 49%Talent
bottom 49%Funding: Raised $480M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series B (Jan 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 119 LinkedIn followers
Funding rounds
- Jan 2026Series B$250M
- Feb 2024Series A$400M
- Dec 2023Seed$80M
Founders & team
Investors
Arch Venture Partners, Orbimed, Fairmount Partners, Sanofi, Point72 Ventures, Farallon Capital Management
Tech stack
AddtoanyAmazon CloudfrontAmazon Web ServicesApache Http ServerApple Icloud MailCookiebot
#5
Series B · Cambridge, Massachusetts · founded 2019$122Mraised▾
Series B · Cambridge, Massachusetts · founded 2019
Developer of messenger ribonucleic acid therapies for immune cell programming. These therapies utilize lipid nanoparticle delivery systems to modify immune cells directly within the body. The technology targets specific cell types to address conditions related to oncology and autoimmunity. The approach focuses on the expression of chimeric antigen receptors to facilitate immune responses against disease targets.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 20%Patents
top 41%Innovation
top 47%Talent
bottom 49%Global
bottom 35%Funding: Raised $122M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (May 2026)
Patents: 18 patents matched (strict assignee match) · 17 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Innovation: 18 patents (top 74% of patent-holders) · 17 filings since 2022 vs 1 in 2017-21
Funding rounds
- May 2026Series B$122M
Founders & team
Investors
Newpath Partners, Hatteras Venture Partners, Arch Venture Partners, Alexandria Venture Investments
#6
Acquired · San Diego, California · founded 2024$206.2Mraised▾
Acquired · San Diego, California · founded 2024
Developer of therapeutics for autoimmune diseases. It focuses on identifying and targeting specific pathways to develop therapies which include CND106 a bispecific antibody that targets and eliminate later stage B-cellsf or autoantibody disease treatment, CND261 targets a broad range of B-cell subtypes for autoimmune diseases.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 17%Growth
top 38%News
top 48%Moat
top 48%Talent
bottom 49%Tech
bottom 38%Funding: Raised $206M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series E (Mar 2026)
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
News: 4 BI events in 12 mo (of 8 tracked, 2 types) · +0% YoY · Top themes: M&A
Audience (LinkedIn): 9k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Mar 2026Series E$505M
- Sep 2024Series D$370M
Founders & team
Investors
Venrock, Fairmont, TCG Crossover, VenBio, Foresite Capital, Third Rock Ventures
Tech stack
CloudflareCloudflare Bot ManagementDreamhostGoogle Font ApiHttp/3Jquery
#7
Orca Bio 🦄Series F · Menlo Park, California · founded 2016 · 66 employees$300Mraised▾
Orca Bio 🦄
Series F · Menlo Park, California · founded 2016 · 66 employees
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 18%Growth
top 26%Moat
top 26%Talent
top 38%Tech
top 40%Market
top 42%Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) · Last round Series F (Jan 2026)
Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 9/10 · Unicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 5.4% of this cohort's audience · 158 engagements/post (1.8× cohort median)
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Series F$250M
- Nov 2019Series D$192M
Founders & team
Investors
Lightspeed Venture Partners, 8VC, DCVC, ND Capital, IMRF, Kaiser Permanente
Tech stack
Amazon Web ServicesApple Icloud MailBackbone.JsBrizy WordpressBunnyBunny Fonts
#8
Series A · Boston, Massachusetts · founded 2022$165Mraised▾
Series A · Boston, Massachusetts · founded 2022
Developer of therapetics for cancer and immunological diseases. It offers multifunctional antibodies that generate immune synapses that precisely activate or inhibit T cells. It has technology platform a solid tumor synergy platform and an I&I platform fornimmune regulation at a tissue-specific level.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Moat
bottom 48%Tech
bottom 47%Global
bottom 36%Market
bottom 32%Funding: Raised $165M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Feb 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 1/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Adagene) announced in 12 mo
Funding rounds
- Feb 2026Series A$52M
- Jul 2024Series A$165M
Founders & team
Investors
Vida Ventures, Cormorant Asset Management, Hillhouse, Goldman Sachs Asset Management, BVF Partners, Janus Henderson Investors
Tech stack
AosCookieyesCore-JsDocusignGatsbyGodaddy
#9
Public · Boulder, Colorado · founded 2007 · 94 employees$34.5Mraised▾
Public · Boulder, Colorado · founded 2007 · 94 employees
Developer of medicines for patients with serious and rare diseases. The company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 29k LinkedIn followers — 6.4% of this cohort's audience
Funding rounds
- May 2026Post IPO$20M
- Feb 2015Series A$8.5M
- Sep 2010Series A$6M
Investors
Fairmount Funds Management, MRLV, Longitude Capital, Broadview Ventures
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementCookieyesDocusignFancybox
#10
Series B · San Francisco, California · founded 2019 · 65 employees$85Mraised▾
Series B · San Francisco, California · founded 2019 · 65 employees
Developer of therapeutics for immunology and cancer. The company is developing transformative therapies by using a technology that maps human tissue and manipulates Tregs and other immune cells in a tissue-specific and disease-specific fashion.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 20%Moat
top 31%News
top 46%Talent
bottom 49%Market
bottom 47%Global
bottom 36%Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series B (Jan 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
News: 2 BI events in 12 mo (of 3 tracked, 3 types) · +100% YoY · Top themes: Announcements, Capital raise
Audience (LinkedIn): 13k LinkedIn followers — 2.8% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jan 2026Series B$50M
- Nov 2024Series B$84M
- Mar 2022Series A$26M
- Jun 2021Series A$59M
Founders & team
Investors
Polaris Partners, SV Health Investors, Lilly, Johnson & Johnson Innovation, Pfizer, Alexandria
#11
Public · Cambridge, Massachusetts · founded 2015 · 51 employees$26.4Mraised▾
Public · Cambridge, Massachusetts · founded 2015 · 51 employees
Precision immunotherapies to transform patients' lives by selectively modulating the immune system. It is a biotechnology company engineering biologics designed to selectively engage and modulate targeted T cells. The company focuses on autoimmune diseases and cancer, aiming to restore immune balance. Their proprietary Immuno-STAT platform enhances a patient’s immune system to potentially restore health. They are developing a novel class of therapeutic biologics. The company's approach involves precision medicine, clinical development, and translational research. They are working towards establishing a new standard of care for diseases that cause human suffering and mortality. They are mobilizing the patient’s immune system to treat serious diseases.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Innovation
top 16%Patents
top 16%News
top 28%Moat
top 29%Growth
top 31%Partners
top 32%Innovation: 491 patents (top 5% of patent-holders) · 336 filings since 2022 vs 155 in 2017-21
Patents: 491 patents matched (strict assignee match) · 336 filings since 2022 vs 155 in 2017-21 · Latest publication 2026
News: 16 BI events in 12 mo (of 40 tracked, 7 types) · +45% YoY · Top themes: Board, Leadership, Earnings
Audience (LinkedIn): 5k LinkedIn followers
Funding rounds
- May 2026Post IPO$30M
- Nov 2022Post IPO$30M
- Dec 2016Series A$16.4M
- Jun 2015Seed$10M
Investors
MDB Capital
Tech stack
Google AnalyticsGoogle Font ApiJqueryJquery MigrateModernizrMysql
#12
Public · Menlo Park, California · founded 2016 · 7 employees$439.6Mraised▾
Public · Menlo Park, California · founded 2016 · 7 employees
Developer of drugs for treating inflammatory diseases. The company has developed Fibrosis & Anti TNF that helps in treating POCD, NACH, Dupuytren's contracture, frozen shoulder, and others. It also provides SCAs that are in the clinical stage and helps in treating diseases like chronic pain, early arthritis, and others. Its drug candidate q7nAChr provides solutions for smoking cessation-induced ulcerative colitis.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 684 LinkedIn followers
Funding rounds
- Jul 2025Post IPO$425M
- Dec 2024Post IPO$2.9M
- Feb 2021Post IPO$11.7M
Investors
Electric Capital, Polychain, GSR, Omicron Technologies, Harbour Island
Funding & investor landscape
$33.3Btotal disclosed funding
447companies funded
1,653disclosed rounds
8rounds last 90 days
Most active investors
Notable founders
Daniel Vitt
Chief Executive Officer · Immunic
Mark McKenna
Founder & CEO · Mirador
Daniel Getts
Co-Founder & CEO · CREATE Medicines
Ken Song
CEO · Candid Therapeutics
Jeroen Bekaert
Co-Founder & COO · Orca Bio
Ivan Dimov
Co-Founder & Co-CEO · Orca Bio
Sanjaya Singh
Founder & Chief Scientific Officer · Third Arc Bio
Peter Lebowitz
CEO · Third Arc Bio
Johnston Erwin
CEO · TRexBio
Clifford Woolf
Co-Founder · Nocion Therapeutics
Bruce Bean
Co-Founder · Nocion Therapeutics
Dimitrios Iliopoulos
Co-founder · Athos Therapeutics
Prism market signals · United States · country-scoped Prism corpus, 11,202,533 docs
Market landscape — 10 sub-themes by coverage
Share of Immunology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 55% → 62% across 2008–2026.
top research entities
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
leading researchers
Sarkar, Subhankar · F. Stephen Hodi · Jedd D. Wolchok · Michael A. Postow · Thomas Powles · Yan-Ruide Li · Abdullah Esmail · Julie R. Brahmer
▲
Breakthroughs3,482 · 25%
▲ 22%→25% share
▲1.1× share momentum0 median citations89% since 2021mostly methods-led
Tumor microenvironment research is surging — U.S. breakthrough papers grew 16-fold (30→481), signaling deep mechanistic focus.
rising sub-themes (early→recent)
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
Newly emergingBreast cancer 0→90 · Reprogramming 0→86 · Flow cytometry 0→44
Landmark Cancer immunotherapy using checkpoint blockade · 6,497 cites
◆
Advancements6,585 · 47%
▼ 51%→47% share
▼0.9× share momentum0 median citations86% since 2021mostly empirical
Transcriptome analysis newly emerged in advancements at 108 papers, reflecting rapid adoption of multi-omic clinical approaches.
rising sub-themes (early→recent)
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
Newly emergingTranscriptome 0→108 · Retrospective cohort study 0→62 · Phases of clinical research 0→59
Landmark Improved Survival with Ipilimumab in Patients with Metastatic Melanoma · 15,037 cites
▼
Concerns2,356 · 17%
▲ 16%→17% share
▲1.1× share momentum0 median citations87% since 2021mostly empirical
Multiple myeloma newly flagged in concerns (54 papers), indicating rising treatment-resistance and refractory-disease challenges.
rising sub-themes (early→recent)
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Newly emergingMultiple myeloma 0→54 · MEDLINE 0→49 · Refractory (planetary science) 0→39
Landmark PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer · 30,895 cites
RESEARCH HOTSPOTS · United States
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston1049 · +0.47
New York931 · +0.44
SF Bay Area496 · +0.50
Philadelphia473 · +0.46
Chicago379 · +0.45
Los Angeles309 · +0.48
Atlanta261 · +0.45
San Diego234 · +0.47
Seattle195 · +0.48
Pittsburgh179 · +0.43
PATENT SIGNAL · United States
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
10,389 filings4,528 assigneespeak 1314/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST223
Common questions
How many Immunology companies are there in United States?
Radar tracks 636 indexable Immunology companies headquartered in United States that meet our profile-completeness bar.
What is the total funding raised by Immunology companies in United States?
The Immunology companies in United States on this list have raised a combined $33.3B in disclosed equity funding across 447 funded companies.
Which is the highest-funded Immunology company in United States?
Sana Biotechnology is the highest-funded Immunology company in United States, with $821M in disclosed equity funding.
How many Immunology companies in United States are funded?
447 of the 636 Immunology companies in United States on this list have disclosed at least one equity funding round.
How many Immunology unicorns are there in United States?
3 Immunology companies in United States on this list are valued at $1B or more.
Who are the top investors in United States Immunology companies?
The most active investors in United States Immunology companies on this list include HHS, RA Capital Management, Orbimed, Alexandria, Janus Henderson Investors.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.